ClinicalTrials.gg
RecruitingNCT04196257Updated Mar 7, 2025

BP1001-A in Patients With Advanced or Recurrent Solid Tumors

A Phase 1 interventional study of BP1001-A (Liposomal Grb2 Antisense Oligonucleotide) and BP1001-A (Liposomal Grb2 Antisense Oligonucleotide) with paclitaxel in Solid Tumor, Adult, Carcinoma, Ovarian Epithelial and Fallopian Tube Neoplasms, sponsored by Bio-Path Holdings, Inc.. Recruiting at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-07.

Primary conditionnone(registry's first term: Carcinoma, Ovarian Epithelial)Many cancersIs this wrong?The study is open to many cancers (its listed conditions name solid tumors in general), and its title does not single out Carcinoma, Ovarian Epithelial, so we do not take that as its main condition. It is not compared with other studies by condition.

Sponsored by Bio-Path Holdings, Inc. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2022; still recruiting 4 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
50
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a phase I, open-label, study of BP1001-A in participants with advanced or recurrent solid tumors. The dose escalation phase will determine the safety and the maximum tolerated dose (MTD) or maximum administered dose (MAD) of BP1001-A as a single agent. After the MTD or MAD of BP1001-A is established, the dose expansion phase will commence and determine the safety, toxicity and response of BP1001-A in combination with paclitaxel.

02

Conditions studied

  • Solid Tumor, Adult
  • Carcinoma, Ovarian Epithelial
  • Fallopian Tube Neoplasms
  • Endometrial Cancer
  • Peritoneal Cancer
  • Solid Tumor

Browse trials for

03

In context

Lead sponsor

Bio-Path Holdings, Inc. is the lead sponsor of 6 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. All participants, ≥ 18 years of age, with histologic evidence of advanced or recurrent solid tumors, who are not candidates for regimens or protocol treatments known to confer clinical benefit.
  2. Performance Status Score of 0 or 1.
  3. Participants must be willing to undergo pre-treatment . Participants who complete 1 cycle of treatment will undergo post-treatment biopsies. Post-treatment biopsies will be offered to participants who do not complete 1 cycle of treatment.
  4. For the dose expansion phase, participants must have recurrent or persistent epithelial ovarian, primary peritoneal, fallopian tube or endometrial tumor and must be participants for whom single agent paclitaxel would be considered a reasonable treatment option.
  5. Endometrial cancer patients with the following histologic epithelial cell types are eligible: Endometrioid adenocarcinoma, serous adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, adenocarcinoma not otherwise specified, mucinous adenocarcinoma, squamous cell, transitional cell carcinoma, and mesonephric carcinoma.

    Ovarian tumor patients with the following histologic epithelial cell types are eligible: High-grade serous carcinoma, endometrioid carcinoma, clear cell carcinoma, squamous carcinoma, transitional cell (Brenner) carcinoma, mixed epithelial-stromal carcinoma, undifferentiated or other epithelial carcinoma.

    Uterine carcinosarcoma and other sarcomas of the uterus are not eligible.

  6. Estimated > 3 months in the Investigator's opinion.
  7. All participants must have per criteria v1.1. Measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest dimension to be recorded). Each lesion must be >/= 20 mm when measured by conventional techniques, including plain x-ray, CT, and MRI, or >/= 10 mm when measured by spiral CT. Measurable disease lesions must be amenable to pre- and post-treatment biopsy.
  8. Participants must have at least one "target lesion" to be used to assess response on this protocol as defined by RECIST v1.1. Tumors within a previously irradiated field will be designated as "non-target" lesions unless progression is documented or a biopsy is obtained to confirm persistence at least 90 days following completion of radiation therapy.
  9. Participants must have adequate:

    1. Bone marrow function: HgB >/= 9 g/dL, WBC >/= 3,000/mcL, >/= 1,500/mcL, >/= 100,000/mcL
    2. Hepatic function: Total within normal institutional limits, and ALT \< 2.5 X institutional
    3. Renal function: Serum creatinine \< 1.5 x ULN or > 60 mL/min according to formula
    4. Neurologic function: Neuropathy (sensory and motor) \</= Grade 1
    5. Blood coagulation parameters: PT such that is \< 1.5 (or an in-range INR, usually between 2 and 3, if a patient is on a stable dose of therapeutic warfarin or low molecular weight heparin) and a PTT \< 1.2 times control
  10. Participants previously treated with docetaxel (regardless of response) are eligible for this trial.
  11. Participants in the dose expansion phase who previously received paclitaxel for primary or recurrent disease are eligible if they did not progress on therapy or relapse within 6 months of completing therapy. Participants with persistent disease at the completion of primary therapy with paclitaxel are not eligible.
  12. Participants should be free of active infection requiring antibiotics, with the exception of uncomplicated UTI.
  13. Any hormonal therapy directed at the malignant tumor must be discontinued at least two weeks prior to BP1001-A treatment. Continuation of hormone replacement therapy is permitted; stable regimens of hormonal therapy for prostate cancer (e.g., leuprolide, a gonadotropin-releasing hormone [GnRH] agonist), ovarian or breast cancer are not exclusionary.
  14. Any other prior therapy directed at the malignant tumor, including immunologic agents, must be discontinued at least four weeks prior to first dose of BP1001-A (6 weeks for nitrosoureas or mitomycin C).
  15. Female participants of must have a negative urine pregnancy test performed within 24 hours prior to the start of study treatment. subjects (defined as no menses for at least 1 year) and surgically sterilized women are not required to undergo a pregnancy test.
  16. Female participants of childbearing potential must agree to use an acceptable method of (i.e., a hormonal contraceptive, intrauterine device, diaphragm with spermicide, condom with spermicide or abstinence) for the duration of the study and for at least 6 months after the last dose of treatment.
  17. Male participants must agree to use an acceptable method of contraception for the duration of the study.
  18. Participants must be willing and able to provide written .

Exclusion criteria

Exclusion Criteria:

  1. For the dose expansion phase, participants must not have low grade serous ovarian carcinoma or mucinous ovarian carcinoma.
  2. For the dose expansion phase, participants must wait at least two weeks after receiving any strong inhibitor, inducer, or substrate of both and CYP2C8 before drug administration.
  3. Participants who had previous bone marrow or hematopoietic stem cell transplant.
  4. Participants may not be receiving any other investigational agents.
  5. Female participants who are pregnant or breast-feeding.
  6. History or evidence upon physical examination of CNS disease, including primary brain tumor, seizures not controlled with standard medical therapy, any , or history of cerebrovascular accident (CVA, stroke), or subarachnoid hemorrhage within 6 months of registration on this study.
  7. Within the past 6 months, participant has had any of the following: myocardial infarction, unstable angina pectoris, coronary/peripheral artery bypass graft, cerebrovascular accident, or transient ischemic attack.
  8. Presence of concurrent conditions that, in the opinion of the Investigator and/or Medical Monitor, may compromise the participant's ability to tolerate study treatment or interfere with any aspect of study conduct or interpretation of results. This includes, but is not limited to, unstable or uncontrolled angina, class III or IV congestive heart failure, uncontrolled and sustained hypertension, cardiac dysrhythmia, or clinically significant baseline abnormality (e.g., >470 msec).
  9. Active pleural effusion or pleural or pericardial effusion with symptoms. Pleural or pericardial effusion that has received treatment and resolved according to the Investigator, is acceptable.
  10. Participants who are ineligible to undergo an MRI scan for reasons such as claustrophobia or the presence of implanted devices or metallic foreign bodies that are not MR compatible, such as ferromagnetic implants or pacers or with a known history of allergic reaction to gadolinium contrast agents.
  11. Any condition which, in the Investigator's opinion, makes the subject unsuitable for trial participation.
  12. A prior history of ≥ Grade 3 to paclitaxel or docetaxel or with products mixed in Cremephor EL or Tween 80®.
  13. Unresolved toxicity higher than Grade 1 attributed to any prior therapy or procedure, excluding alopecia.
  14. Substance abuse, medical, psychological, or social conditions that may interfere with the patient's participation in the study or evaluation of the study results.
  15. Participants with infection who have \< 350 cells/mcL or with clinically active or C infection.
  16. Participants who have a major surgical procedure, open , dental extractions, or other dental surgery/procedure that results in an open wound, or significant traumatic injury within 28 days prior to the first date of treatment on this study, or anticipation of need for major surgical procedure during the course of the study; patients with placement of vascular access device or core biopsy within 7 days prior to registration.
  17. (For dose expansion phase) Subjects ineligible or unable to receive paclitaxel as treatment for their disease.
Terms in these criteria, in plain language(30)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    BP1001-A monotherapy

    Dose escalation of BP1001-A monotherapy

    Drug: BP1001-A (Liposomal Grb2 Antisense Oligonucleotide)

  • Experimental
    BP1001-A and Paclitaxel

    Dose expansion of selected dose of BP1001-A with paclitaxel

    Drug: BP1001-A (Liposomal Grb2 Antisense Oligonucleotide) with paclitaxel

Interventions

  • DrugPrexigebersenStudies of PrexigebersenPrexigebersen pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Dose escalation of BP1001-A intravenously (IV), twice weekly for 4 weeks (28-day cycle) for 6 cycles.

  • DrugBP1001-A (Liposomal Grb2 Antisense Oligonucleotide) with paclitaxel

    Drug page: PrexigebersenStudies of PrexigebersenPrexigebersen pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Dose expansion of BP1001-A IV twice weekly (Maximum tolerated dose or Maximum admistered dose) plus paclitaxel IV weekly for 4 weeks (28-day cycle) for 6 cycles.

06

What researchers measure

Primary outcomes

  1. Identify Dose Limiting Toxicity (DLT) of BP1001-A

    Identify DLT of BP1001-A using non-hematologic and and hematologic measures per NCI CTCAE criteria

    Time frame: 30 days

  2. Identify maximum tolerated dose (MTD) of BP1001-A

    Identify MTD based on dose limiting toxicities (DLT) of BP1001-A using non-hematologic and hematologic measures per NCI CTCAE criteria

    Time frame: 30 days

  3. Identify and grade Treatment-Emergent Adverse Events (TEAE) of BP1001-A

    Identify and grade TEAE of escalating doses of BP1001-A using non-hematologic and hematologic measures per NCI CTCAE criteria

    Time frame: 30 days

  4. Identify and grade Treatment-Emergent Adverse Events (TEAE) of BP1001-A in combination with paclitaxel

    Identify and grade TEAE of BP1001-A in combination with paclitaxel using non-hematologic and hematologic measures per NCI CTCAE criteria

    Time frame: 30 days

Secondary outcomes

  1. Frequency and severity of Adverse Events (AEs) of BP1001-A monotherapy and in combination with paclitaxel

    Determine frequency and grade of AEs per NCI CTCAE criteria

    Time frame: 30 days

  2. Determine objective response rate (ORR) by biopsy

    Determine ORR by tumor biopsy using Response Criteria in Solid Tumors (RECIST)

    Time frame: 180 days

  3. Determine objective response rate (ORR) by imaging

    Determine ORR by MRI or CT imaging using Response Criteria in Solid Tumors (RECIST)

    Time frame: 180 days

  4. Describe duration of overall response (OR)

    Describe duration of OR using tumor biopsy per RECIST

    Time frame: 180 days

  5. Describe duration of objective response (OR)

    Describe duration of OR using MRI or CT imaging per RECIST

    Time frame: 180 days

  6. Describe duration of stable disease by imaging

    Describe duration of stable using MRI or CT imaging per RECIST

    Time frame: 180 days

  7. Describe duration of stable disease by tumor biopsy

    Describe duration of stable disease using tumor biopsy per RECIST

    Time frame: 180 days

  8. Describe progression-free survival (PFS) per RECIST by biopsy

    Describe PFS using tumor biopsy per RECIST

    Time frame: 360 days

  9. Describe progression-free survival (PFS) per RECIST by imaging

    Describe PFS using MRI or CT imaging per RECIST

    Time frame: 360 days

  10. Determine plasma pharmacokinetics (PK) of BP1001-A monotherapy and in combination with paclitaxel (Cmax)

    Evaluate in vivo PK of BP1001-A monotherapy and BP1001-A in combination with paclitaxel using maximum plasma drug concentration (Cmax)

    Time frame: 30 days

  11. Determine plasma pharmacokinetics (PK) of BP1001-A monotherapy and in combination with paclitaxel (Tmax)

    Evaluate in vivo PK of BP1001-A monotherapy and BP1001-A in combination with paclitaxel using time of maximal observed concentration (Tmax)

    Time frame: 30 days

  12. Determine plasma pharmacokinetics (PK)of BP1001-A monotherapy and in combination with paclitaxel (AUC)

    Evaluate in vivo PK of BP1001-A monotherapy and BP1001-A in combination with paclitaxel using Area Under the Curve (AUC)

    Time frame: 30 days

  13. Determine plasma pharmacokinetics of BP1001-A monotherapy and in combination with paclitaxel (CL)

    Evaluate in vivo PK of BP1001-A monotherapy and BP1001-A in combination with paclitaxel using clearance rate (CL)

    Time frame: 30 days

  14. Determine half-life plasma pharmacokinetics (PK) of BP1001-A monotherapy and in combination with paclitaxel (t1/2)

    Evaluate in vivo PK of BP1001-A monotherapy and BP1001-A in combination with paclitaxel using mean terminal elimination half life (t1/2)

    Time frame: 30 days

  15. Frequency and severity of AEs of BP1001-A in combination with paclitaxel

    Determine frequency and grade of AEs of BP1001-A in combination with paclitaxel per NCI CTCAE criteria

    Time frame: 30 days

07

Study locations

4 of 4 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2022 (actual). Primary completion is estimated for Jul 2027, 59 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2019
First posted
Dec 12, 2019
StartActual
Aug 19, 2022
Primary completionEst.
Jul 2027
CompletionEst.
Oct 2027
Last update
Mar 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04196257
Lead sponsor
Bio-Path Holdings, Inc.
Responsible party
Sponsor
First posted
Dec 12, 2019
Start date
Aug 19, 2022
Primary completion
Jul 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Mar 7, 2025

Study contacts

Brian Forbes
Contact
bforbes@biopathholdings.com
832-742-1365
Michael Hickey
Contact
mhickey@biopathholdings.com
832-742-1361

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Prexigebersen

Start the discussion